Early stage biopharmaceutical company focused
on the use of psilocybin proprietary therapeutics.
What We Know.
In supervised early lab studies, psychedelic drugs like psilocybin, ketamine and LSD have been shown to produce neurological responses that could help treat conditions like end-of-life anxiety, Alzheimer’s, depression, addiction, PTSD and obsessive-compulsive disorder.
What We Don’t Know.
Psilocybin therapy studies have had a promising start, but research is just in it’s infancy. There is a great need for privately funded clinical research in the space-Silo Pharma will be one of the first companies to address this need. One significant recent validation was John Hopkins Medicine starting a new Center for Psychedelic and Consciousness Research with $17 million in funding. The Center will conduct research in the treatment of depression, addiction, PTSD and Alzheimer’s disease.
What it Means for You.
For patients with anxiety, depression, or addiction, medical psychedelics could become a promising treatment. For now, there’s more research to be done before they’re used as medicine outside of the lab.
What it Means for Policy.
The U.S. Food and Drug Administration (FDA) authorized Breakthrough Therapy Designation for Compass Pathways Ltd. psilocybin therapy for depression in 2018. Johnson and Johnson’s (JNJ) ketamine derived nasal spray (Spravato) was approved in March 2019 for treatment-resistant depression. Decriminalization occurred last year in the cities of Denver, Oakland and Santa Cruz. At the State level, ballot measures for decriminalization are out for signature in California and Oregon.